title: EGFR targeted PLGA nanoparticles using gemcitabine for treatment of pancreatic cancer.
abstract: The present study aimed to prepare and characterize anti EGFR monoclonal antibody (mab) conjugated Gemcitabine loaded PLGA nanoparticles for their selective delivery to pancreatic cells and evaluation of the systems in vitro. It was observed that direct covalent coupling of antibodies to glutaraldehyde activated nanoparticles is an appropriate method to achieve cell-type specific drug carrier systems based on polymeric nanoparticles that have potential to be applied for targeted chemotherapy in EGFR positive cancer.
authors.affiliation: Nanomedicine Research Centre, Department of Pharmaceutics, I.S.F College of Pharmacy, Moga 142001, India.
authors.forename: Sahil
authors.initials: S
authors.lastname: Aggarwal
authors.forename: Sachin
authors.initials: S
authors.lastname: Yadav
authors.forename: Swati
authors.initials: S
authors.lastname: Gupta
mesh_terms: D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics / Q000627:therapeutic use; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D004339:Drug Compounding / Q000379:methods; D066246:ErbB Receptors / Q000378:metabolism*; D006801:Humans; D019344:Lactic Acid / Q000737:chemistry*; D053769:Nanocapsules / Q000008:administration & dosage / Q000737:chemistry*; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D011100:Polyglycolic Acid / Q000737:chemistry*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D000911:Antibodies, Monoclonal; D053769:Nanocapsules; D003841:Deoxycytidine; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; C512478:EGFR protein, human; D066246:ErbB Receptors; D000093542:Gemcitabine